Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-09-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司第四届董事会独立董事关于第四届董事会第十八次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding their prior approval opinion on a specific board meeting agenda item about terminating a licensing cooperation agreement. It is a formal opinion related to board matters and does not contain financial data, earnings, or report publication information. It is not an annual or interim report, nor an earnings release or audit report. The content focuses on board-level decisions and approvals, which aligns with Board/Management Information filings. The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is MANG (Board/Management Information).
2021-09-27 Chinese
中信证券关于百克生物半年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2021年半年度持续督导跟踪报告" which translates to "2021 Half-Year Continuous Supervision Follow-up Report" issued by the sponsor (中信证券) for the company 长春百克生物科技股份公司. It references the first half of 2021 (1-6 months) and contains detailed financial data, risk analysis, compliance with regulations, use of raised funds, and management shareholding information. The document is a comprehensive report on the sponsor's continuous supervision work for the listed company during the half-year period, including financial performance and compliance. It is not a full annual report (10-K), nor a quarterly report (IR) in the traditional sense, but a specialized regulatory continuous supervision report required for companies listed on the STAR Market (科创板) in China. This type of report is distinct from standard interim reports and is a regulatory continuous supervision follow-up report by the sponsor. Given the detailed financial data and the nature of the report, it fits best under the category of Regulatory Filings (RNS) as it is a regulatory mandated continuous supervision report rather than a standard financial report like an interim report or annual report. The document length is over 11,000 characters and contains substantive content, so it is not a mere announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2021-08-13 Chinese
长春百克生物科技股份公司关于参股公司拟进行清算的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun Baike Biotechnology Co., Ltd. regarding the liquidation of an associate company, Changchun Baiyi Pharmaceutical Co., Ltd. It details the background of the associate company, the cessation of its main project, and the planned liquidation process. The document is an official notice about a corporate event affecting the company but does not contain financial statements, audit information, or detailed financial results. It is not a full annual or interim report, nor is it a regulatory certification or voting result. The content fits best as a general regulatory announcement informing shareholders and the public about a significant corporate development. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not a report publication announcement or a detailed financial report.
2021-08-13 Chinese
关于确认长春百克生物科技股份公司与宁波纯派农业科技有限公司日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Changchun Baike Biotechnology Co., Ltd. regarding the confirmation of daily related-party transactions with Ningbo Chunpai Agricultural Technology Co., Ltd. It details the nature of the transactions, the approval process by the board and independent directors, and the compliance with relevant stock exchange rules. The document includes transaction amounts, shareholder structure, and opinions from independent directors and the sponsoring institution. It is a regulatory announcement about related-party transactions, not a full financial report or audit report. The document length is 4287 characters, which is relatively short and focused on a specific corporate disclosure. This fits the category of a Regulatory Filing (RNS) as it is a compliance announcement about related-party transactions and approvals, rather than a full report or financial statement.
2021-08-13 Chinese
长春百克生物科技股份公司2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年半年度报告" which translates to "2021 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, R&D progress, and other comprehensive information typical of an interim or quarterly report. The report period is specified as January 1, 2021 to June 30, 2021, confirming it covers a half-year period. The document includes financial statements, management analysis, risk disclosures, and other substantive financial and operational data. It is not a brief announcement or a certification letter but a full detailed report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-13 Chinese
长春百克生物科技股份公司第四届监事会第九次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 9th meeting of the 4th Supervisory Board of Changchun Baike Biotechnology Co., Ltd. It includes the approval of the 2021 semi-annual report and a special report on the use of raised funds, as well as confirmation of related party transactions. The document is short (1365 characters) and primarily reports on the meeting decisions rather than containing the full semi-annual report or detailed financial data. It is therefore not the interim/quarterly report itself but an announcement related to it. This fits best with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-08-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.